Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)

Multiple Myeloma Clinical Trial

— KarMMa-3  

Official title:

A Phase 3, Multicenter, Randomized, Open-label Study to Compare the Efficacy and Safety of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) (KarMMa-3)

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT03651128
• Other study ID #: BB2121-MM-003
• Secondary ID: U1111-1217-99882
• Status: Active, not recruiting
• Phase: Phase 3
• Start date: April 16, 2019
• Est. completion date: April 8, 2027

Study information

• Verified date: December 2022
• Source: Celgene
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a multicenter, randomized, open-label, Phase 3 study comparing the efficacy and safety of bb2121 versus standard regimens in subjects with relapsed and refractory multiple myeloma (RRMM).

The study is anticipated to randomize approximately 381 subjects with RRMM. Approximately 254 subjects will be randomized to Treatment Arm A and approximately 127 subjects will be randomized to Treatment Arm B.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 381
• Est. completion date: April 8, 2027
• Est. primary completion date: April 8, 2027
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

Subjects must satisfy the following criteria to be enrolled in the study:

1. Subject is = 18 years of age at the time of signing the informed consent form (ICF).

2. Subject must understand and voluntarily sign an ICF prior to any study-related assessments/procedures being conducted.

3. Subject is willing and able to adhere to the study visit schedule and other protocol requirements within this protocol and for a subject randomized to Treatment Arm A, subject agrees to continued follow-up for up to 15 years as mandated by the regulatory guidelines for gene therapy trials.

4. Subject has documented diagnosis of MM and measurable disease, defined as:

• M-protein (serum protein electrophoresis [sPEP] or urine protein electrophoresis [uPEP]): sPEP = 0.5 g/dL or uPEP = 200 mg/24 hours and/or

• Light chain MM without measurable disease in the serum or urine: Serum immunoglobulin free light chain = 10 mg/dL (100 mg/L) and abnormal serum immunoglobulin kappa lambda free light chain ratio

5. Subject has received at least 2 but no greater than 4 prior MM regimens.

6. Subject has received prior treatment with DARA, a proteasome inhibitor- and an immunomodulatory compound-containing regimen for at least 2 consecutive cycles.

7. Subject must be refractory to the last treatment regimen. Refractory is defined as documented progressive disease during or within 60 days (measured from the last dose of any drug within the regimen) of completing treatment with the last anti-myeloma regimen before study entry.

8. Subject achieved a response (minimal response [MR] or better) to at least 1 prior treatment regimen.

9. Subject has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

10. Recovery to Grade 1 or baseline of any non-hematologic toxicities due to prior treatments, excluding alopecia and Grade 2 peripheral neuropathy.

11. Adequate vascular access for leukapheresis

12. Females of childbearing potential (FCBP) must:

a. Have negative pregnancy test(s) as verified by the Investigator. This applies even if the subject practices true abstinence from heterosexual contact.

b. Either practice true abstinence from heterosexual contact or agree to use, and be able to comply with, effective measures of contraception without interruption.

c. Agree to abstain from breastfeeding during study participation. d. Refrain from tissue donation including egg cell donation or any other tissue/blood/organ donations.

13. Male subjects must:

a. Practice true abstinence or agree to use a condom during sexual contact with a pregnant female or a female of childbearing potential while participating in the study, during dose interruptions, even if he has undergone a successful vasectomy.

b. Refrain from tissue donation including sperm or any other tissue/blood/organ donations.

14. Only subjects that would be considered for any of the 5 proposed standard regimens (DPd, DVd, IRd, Kd, or EPd), as judged by the investigator, should be included in the study.

Exclusion Criteria:

The presence of any of the following will exclude a subject from enrollment:

1. Subject has any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the study.

2. Subject has any condition including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study.

3. Subject has any condition that confounds the ability to interpret data from the study.

4. Subject has nonsecretory multiple myeloma (MM).

5. Subject has any of the following laboratory abnormalities:

a. Absolute neutrophil count (ANC) < 1,000/µL b. Platelet count: < 75,000/µL in subjects in whom < 50% of bone marrow nucleated cells are plasma cells and platelet count < 50,000/µL in subjects in whom = 50% of bone marrow nucleated cells are plasma cells (it is not permissible to transfuse a subject to reach this level) c. Hemoglobin < 8 g/dL (< 4.9 mmol/L) (it is not permissible to transfuse a subject to reach this level) d. Serum creatinine clearance (CrCl) < 45 mL/min e. Corrected serum calcium > 13.5 mg/dL (> 3.4 mmol/L) f. Serum aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 2.5 × upper limit of normal (ULN) g. Serum total bilirubin > 1.5 × ULN or > 3.0 mg/dL for subjects with documented Gilbert's syndrome h. International normalized ratio (INR) or activated partial thromboplastin time (aPTT) > 1.5 × ULN, or history of Grade = 2 hemorrhage within 30 days, or subject requires ongoing treatment with chronic, therapeutic dosing of anticoagulants (eg, warfarin, low molecular weight heparin, Factor Xa inhibitors)

6. Subject has inadequate pulmonary function defined as oxygen saturation (SaO2) < 92% on room air.

7. Subject has prior history of malignancies, other than MM, unless the subject has been free of the disease for = 5 years • Basal cell carcinoma of the skin

• Squamous cell carcinoma of the skin

• Carcinoma in situ of the cervix

• Carcinoma in situ of the breast

• Incidental histologic finding of prostate cancer (T1a or T1b using the tumor, nodes, metastasis [TNM] clinical staging system) or prostate cancer that can be treated with curative intent

8. Subject has active or history of plasma cell leukemia, Waldenstrom's macroglobulinemia, POEMS syndrome or amyloidosis.

9. Subject with known central nervous system (CNS) involvement with myeloma.

10. Subject has clinical evidence of pulmonary leukostasis and disseminated intravascular coagulation.

11. Subject has known chronic obstructive pulmonary disease (COPD) with a forced expiratory volume in 1 second (FEV1) 50% of predicted normal.

12. Subject has a history or presence of clinically relevant CNS pathology such as epilepsy, seizure, paresis, aphasia, stroke, subarachnoid hemorrhage or other CNS bleed, severe brain injuries, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome, or psychosis.

13. Subject was treated with DARA in combination with POM with or without dex (DP±d) as part of their most recent anti-myeloma treatment regimen, cannot receive DPd as bridging therapy but may receive DVd, IRd, Kd or EPdas bridging as per Investigator's discretion if randomized to Treatment Arm A.

14. Subject was treated with DP±d as part of their most recent anti-myeloma treatment regimen, cannot receive DPd if randomized to Treatment Arm B but may receive DVd, IRd, Kd, or EPd as per Investigator's discretion.

15. Subject was treated with DARA in combination with BTZ with or without dexamethasone (DV±d) as part of their most recent anti-myeloma treatment regimen, cannot receive DVd as bridging therapy but may receive DPd, IRd, Kd, or EPd as bridging as per Investigator's discretion if randomized to Treatment Arm A.

16. Subject was treated with DV±d as part of their most recent anti-myeloma treatment regimen, cannot receive DVd if randomized to Treatment Arm B but may receive DPd, IRd, Kd, or EPd as per Investigator's discretion.

17. Subject was treated with IXA in combination with LEN with or without dexamethasone (IR±d) as part of their most recent anti-myeloma treatment regimen, cannot receive IRd as bridging therapy but may receive DPd, DVd, Kd, or EPd as bridging as per Investigator's discretion if randomized to Treatment Arm A.

18. Subject was treated with IR±d as part of their most recent anti-myeloma treatment regimen, cannot receive IRd if randomized to Treatment Arm B but may receive DPd, DVd, Kd, or EPd as per Investigator's discretion.

19. Previous history of an allogeneic hematopoietic stem cell transplantation, treatment with any gene therapy-based therapeutic for cancer, investigational cellular therapy for cancer or BCMA targeted therapy.

20. Subject has received autologous stem cell transplantation (ASCT) within 12 weeks prior to randomization.

21. Subject has received any of the following within the last 14 days prior to randomization:

a. Plasmapheresis b. Major surgery (as defined by the Investigator) c. Radiation therapy other than local therapy for myeloma-associated bone lesions d. Use of any investigational agents and systemic anti-myeloma drug therapy

22. Echocardiogram (ECHO) or multigated acquisition (MUGA) with left ventricular ejection fraction (LVEF) < 45%.

23. Ongoing treatment with chronic immunosuppressants (eg, cyclosporine or systemic steroids at any dose). Intermittent topical, inhaled or intranasal corticosteroids are allowed.

24. Subject is positive for human immunodeficiency virus (HIV-1 and HIV-2), chronic or active hepatitis B or active hepatitis A or C.

25. Subject has uncontrolled systemic fungal, bacterial, viral or other infection (defined as exhibiting ongoing signs/symptoms related to the infection and without improvement, despite appropriate antimicrobial treatment) or requiring IV antimicrobials for management.

26. Subject has a history of class III or IV congestive heart failure (CHF) or severe nonischemic cardiomyopathy, unstable or poorly controlled angina, myocardial infarction, or ventricular arrhythmia within the previous 6 months prior to randomization.

27. Hypersensitivity to DARA, thalidomide, lenalidomide, POM, BTZ, IXA, CFZ, ELO or dexamathasone. This includes rash = Grade 3 during prior thalidomide, POM or lenalidomide therapy.

28. Subject with known hypersensitivity to any component of bb2121 product, cyclophosphamide, fludarabine, and/or tocilizumab or hypersensitivity to the excipients contained in the formulation of DARA, POM, LEN, IXA, BTZ, CFZ, ELO or dexamethasone.

29. Subject is a female who is pregnant, nursing, or breastfeeding

30. For a subject randomized to Treatment Arm B and will be on a POM- or LEN-containing regimen; unable or unwilling to undergo protocol required thromboembolism prophylaxis.

28 Subject is intolerant to bortezomib, or has acute diffuse infiltrative pulmonary and pericardial disease, subject cannot receive DVd as bridging therapy if randomized to Treatment Arm A or cannot receive DVd if randomized to Treatment Arm B.

31. Subject was treated with K±d as part of their most recent anti-myeloma treatment regimen, cannot receive Kd if randomized to Treatment Arm B but may receive DPd, DVd, IRd or EPd as per Investigator's discretion.

32. Subject was treated with EP±d as part of their most recent anti-myeloma treatment regimen, cannot receive EPd if randomized to Treatment Arm B but may receive DPd, DVd, Kd or IRd as per Investigator's discretion.

Related Conditions & MeSH terms

• Multiple Myeloma
• Neoplasms, Plasma Cell

Intervention

Biological:
• bb2121
bb2121

Drug:
• Daratumumab
Daratumumab
• Pomalidomide
Pomalidomide
• Dexamethasone
Dexamethasone
• Bortezomib
Bortezomib
• Ixazomib
Ixazomib
• Lenalidomide
Lenalidomide
• Carfilzomib
Carfilzomib
• Elotuzumab
Elotuzumab

Locations

Country	Name	City	State
Belgium	Local Institution - 202	Leuven
Canada	Local Institution - 302	Calgary	Alberta
Canada	Local Institution - 303	Toronto	Ontario
France	Local Institution - 402	Lille Cedex
France	Local Institution - 403	Nantes
France	Local Institution - 400	Paris
France	Local Institution - 401	Toulouse CEDEX 9
Germany	Local Institution - 513	Dusseldorf
Germany	Local Institution - 514	Hamburg
Germany	Local Institution - 512	Heidelberg
Germany	Local Institution - 515	Köln
Germany	Local Institution - 511	Würzburg
Italy	Local Institution - 611	Bologna
Japan	Local Institution - 806	Bunkyo-ku
Japan	Local Institution - 804	Isehara City, Kanagawa
Japan	Local Institution - 807	Nagoya
Japan	Local Institution - 805	Shibuya-ku
Netherlands	Local Institution - 650	Amsterdam
Netherlands	Local Institution - 651	Rotterdam
Norway	Local Institution - 700	Oslo
Spain	Local Institution - 750	Pamplona
Spain	Local Institution - 751	Salamanca
Sweden	Local Institution - 800	Stockholm
Switzerland	Local Institution - 251	Bern
United Kingdom	Local Institution - 850	Leeds
United Kingdom	Local Institution - 851	London
United States	University Of Michigan Comprehensive Cancer Center	Ann Arbor	Michigan
United States	Local Institution - 131	Atlanta	Georgia
United States	Local Institution - 140	Atlanta	Georgia
United States	Local Institution - 142	Aurora	Colorado
United States	Local Institution - 104	Baltimore	Maryland
United States	Local Institution - 109	Birmingham	Alabama
United States	Local Institution - 123	Boston	Massachusetts
United States	Local Institution - 134	Boston	Massachusetts
United States	Local Institution - 139	Chicago	Illinois
United States	Local Institution - 103	Dallas	Texas
United States	Local Institution - 118	Dallas	Texas
United States	Local Institution - 113	Durham	North Carolina
United States	Local Institution - 138	Hackensack	New Jersey
United States	Local Institution - 132	Houston	Texas
United States	Local Institution - 100	Indianapolis	Indiana
United States	Local Institution - 108	Jacksonville	Florida
United States	Local Institution - 122	Los Angeles	California
United States	Local Institution - 145	Los Angeles	California
United States	Local Institution - 107	Madison	Wisconsin
United States	Local Institution - 106	Nashville	Tennessee
United States	Local Institution - 115	New York	New York
United States	Local Institution - 119	New York	New York
United States	Local Institution - 135	New York	New York
United States	Local Institution - 124	Palo Alto	California
United States	Local Institution - 110	Philadelphia	Pennsylvania
United States	Local Institution - 111	Philadelphia	Pennsylvania
United States	University of Pittsburgh Medical Center William M. Cooper Ambulatory Care Pavillion	Pittsburgh	Pennsylvania
United States	Local Institution - 125	Rochester	Minnesota
United States	Local Institution - 114	Saint Louis	Missouri
United States	Local Institution - 136	Salt Lake City	Utah
United States	Local Institution - 141	Scottsdale	Arizona
United States	Local Institution - 105	Seattle	Washington
United States	Local Institution - 102	Tampa	Florida
United States	Local Institution - 112	Westwood	Kansas

Sponsors (1)

Lead Sponsor	Collaborator
Celgene

Countries where clinical trial is conducted

United States,  Belgium,  Canada,  France,  Germany,  Italy,  Japan,  Netherlands,  Norway,  Spain,  Sweden,  Switzerland,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Progression-free Survival (PFS)	Time from randomization to the first documentation of progressive disease based on the International Myeloma Working Group (IMWG) Uniform Response Criteria for Multiple Myeloma assessed by an independent response committee (IRC) or death due to any cause, whichever occurs first.	Minimum of 5 years from randomization
Secondary	Overall Survival (OS)	Time from randomization to time of death due to any cause	Minimum of 5 years from randomization
Secondary	Event-free Survival (EFS)	Time from randomization to the first documentation of progressive disease, first day when subject receives another anti-myeloma treatment or death due to any cause, whichever occurs first	Minimum of 5 years from randomization
Secondary	Overall Response Rate (ORR)	Percentage of subjects who achieved partial response (PR) or better according to IMWG Uniform Response Criteria for Multiple Myeloma as assessed by an IRC	Minimum of 5 years from randomization
Secondary	Minimal Residual Disease (MRD)	Percentage of MRD evaluable subjects that are MRD negative (defined at a minimum of 1 in 10^5 nucleated cells) using flow cytometry (EuroFlow) and next generation sequencing (NGS)	Minimum of 5 years from randomization
Secondary	Complete Response (CR) Rate	Percentage of subjects who achieved CR or better according to IMWG Uniform Response Criteria for Multiple Myeloma as assessed by an IRC	Minimum of 5 years from randomization
Secondary	Duration of Response (DOR)	Time from first documentation of response (PR or better) to first documentation of disease progression or death from any cause, whichever occurs first	Minimum of 5 years from randomization
Secondary	Time to Response (TTR)	TTR is calculated as the time from randomization to the initial documented response (PR or better) based on IMWG guideline for responders	Minimum of 5 years from randomization
Secondary	Adverse Events (AEs)	Number of participants with adverse events	Minimum of 5 years from randomization
Secondary	Pharmacokinetics- Cmax	Maximum peak in bb2121 chimeric antigen receptor (CAR) T cells	Minimum 5 years after bb2121 infusion
Secondary	Pharmacokinetics- tmax	Time to peak of bb2121 CAR T cells	Minimum 5 years after bb2121 infusion
Secondary	Pharmacokinetics- AUC	Area under the curve of CAR T cells	Minimum 5 years after bb2121 infusion
Secondary	Pharmacokinetics- t-last	Time to last measurable CAR T cells	Minimum 5 years after bb2121 infusion
Secondary	Pharmacokinetics- AUC0-28days	Area under the curve of CAR T cells from time zero to Day 28	Minimum 5 years after bb2121 infusion
Secondary	Subject-reported outcomes as measured by European Organization for Research and Treatment of Cancer Quality-of-Life questionnaire (EORTC-QLQ-C30)	Questionnaire will be used as a measure of health-related quality of life	Minimum of 5 years from randomization
Secondary	Subject-reported outcomes as measured by EuroQoL Group European Quality of Life-5 Dimensions health state classifier to 5 Levels (EQ-5D-5L) Health Questionnaire	Is a standardized measure of health status developed by the EuroQol Group in order to provide a simple, generic measure of health for clinical and economic appraisal	Minimum of 5 years from randomization
Secondary	Subject-reported outcomes as measured by European Quality of Life Multiple Myeloma Module (EORTC-QLQ-MY20)	Is a 20-item myeloma module intended for use among patients varying in disease stage and treatment modality	Minimum of 5 years from randomization
Secondary	Time to next antimyeloma treatment	Time from randomization to first day when subject receives another anti-myeloma treatment	Minimum of 5 years from randomization
Secondary	Progression-free survival after next line therapy (PFS2)	Time from randomization to second objective disease progression or death from any cause, whichever is first	Minimum of 5 years from randomization

External Links

•   BMS Clinical Trial Information
•   BMS Clinical Trial Patient Recruiting